Alloplex biotherapeutics receives FDA fast track designation for SUPLEXA in colorectal cancer indication

Designation recognizes the potential of SUPLEXA therapeutic cells in addressing high unmet need in patients with solid tumors Alloplex Biotherapeutics Inc. (‘Alloplex’) announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to SUPLEXA for the treatment of patients with colorectal cancer of the MSI-H phenotype.